Medical AI company Lunit said Thursday that it has partnered with Volpara Health to provide SecondReadAI, an AI solution for breast cancer screening, to Rezolut, a large imaging diagnostics platform company with more than 40 imaging centers across the U.S.

SecondReadAI is an integrated AI solution for breast cancer screening based on Lunit's two-dimensional (2D) AI image analysis solution Lunit INSIGHT MMG and three-dimensional (3D) mammography AI image analysis solution Lunit INSIGHT DBT.

Rezolut will use the SecondReadAI solution to analyze more than 300,000 medical images per year at its imaging centers across the U.S.

The SecondReadAI will likely increase profitability significantly thanks to a new business model in which patients, rather than hospitals, pay directly for the AI solution applied to breast cancer screening and image reading.

In addition, Rezolut plans to expand the SecondReadAI's application to over 60 clinics connected to its regional centers.

“The launch of SecondReadAI is an important step forward in our mission to transform healthcare with innovative technologies,” Rezolut CEO Kim Jin said. “We look forward to enhancing the diagnostic capabilities of medical professionals and improving patient care by introducing AI products with improved accuracy and efficiency in the diagnostic process.”

Lunit CEO Beomseok Brandon Suh said, “This agreement is significant because it marks the first collaboration since the acquisition of Volpara and the first time Lunit AI products have been distributed through Volpara's U.S. distribution network. We will continue to focus on product enhancements and expanding distribution channels to maximize the synergies of the acquisition.”